Tolerability and Safety and Health Outcomes in Relapsing... | NCT01127750 | Trialant

Tolerability and Safety and Health Outcomes in Relapsing... | NCT01127750 | Trialant

Outcomes Module

Secondary Outcomes

Measure	Description	Time Frame
Incidence of macular edema		4 months
Incidence of bradyarrhythmic electrocardiograms (ECGs)		4 months
Patient reported outcomes indices in multiple sclerosis (PRIMUS), short form health survey-12, and treatment satisfaction questionnaire for medication (TSQM-9)

Contacts/Locations Module

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
24221641	Result	Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L; FIRST Study Investigators. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. 2014 Feb;261(2):267-76. doi: 10.1007/s00415-013-7115-8. Epub 2013 Nov 13.